NarghileDNA DamageNCT07141823
Oxidative DNA Damage Enhancement by Vitamin C Among Narghile Smokers and Non-smokers
A study testing Vitamin C (Ascorbic Acid) regularly has been taken in people with Narghile, run by Nora Tariq Mohammed at 1 site in Iraq.
Trial summary
This study aims to evaluate oxidative DNA damage among hookah smokers compared to non-smokers by measuring biomarkers of oxidative stress in blood samples. The objective is to determine the impact of hookah smoking on DNA integrity and overall oxidative status in adults. Read more about this study
- Who is it for?
- Ages 18 to 30 months
- Conditions the study is for
- Narghile
- What is being tested?
- Vitamin C (Ascorbic Acid) regularly has been taken
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 96 participants
- Where
- 1 siteIraq
- Study dates
- 15 Oct 2024to 10 Mar 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 months
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Adults aged 18-30 years
- Current narghile (hookah) smokers for at least 1 year
- Willing to provide informed consent
Who cannot join
- Healthy participant
Trial locations and contacts
1 site in 1 country.
About this study
This study aims to evaluate oxidative DNA damage among hookah smokers compared to non-smokers by measuring biomarkers of oxidative stress in blood samples. The objective is to determine the impact of hookah smoking on DNA integrity and overall oxidative status in adults.
Read the detailed description
Hookah smoking has become increasingly popular in many regions, yet its potential impact on oxidative stress and DNA integrity is not fully understood. This study aims to investigate the level of oxidative DNA damage among hookah smokers compared to non-smokers by analyzing biomarkers in blood samples. A case-control observational design will be used, involving two groups of adult participants: regular hookah smokers and age-matched non-smokers. Blood samples will be collected from all participants and analyzed for markers of oxidative stress, including 8-hydroxy-2'-deoxyguanosine (8-OHdG) and malondialdehyde (MDA), using validated biochemical methods. The findings are expected to provide insights into the biological consequences of hookah smoking and support the development of public health interventions.
- Conditions
- Narghile
- Being tested
- Vitamin C (Ascorbic Acid) regularly has been taken
- Keywords
- DNA damage, Oxidative stress ,MDA, vitamin C
- Medical subject headings
- Water Pipe Smoking
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vitamin C (Ascorbic Acid) regularly has been takenDietary supplement
| Study group | Role | What they receive |
|---|---|---|
| Narghile nonsmokers vitamin C taking | Experimental | this group of participant take vitamin C for one month, and they are healthy volunteers Receives: Dietary Supplement: Vitamin C (Ascorbic Acid) regularly has been taken |
| Narghile smokers | Experimental | this group take vitamin c supplent for one month period and are healthy. Receives: Dietary Supplement: Vitamin C (Ascorbic Acid) regularly has been taken |
What is being measured
The primary outcome is the main question the study is designed to answer.
Oxidative DNA damage
Measurement of plasma MDA concentration using the thiobarbituric acid reactive substances (TBARS) method to assess oxidative stress in participants before and after 1-month Vitamin C supplementation and measuring oxidative stress marker and TAOC
Measured: Baseline and after 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Aug 2025
- Study start15 Oct 2024
- Primary completion10 Dec 2024
- Study completion10 Mar 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NarghileStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 96 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nora Tariq Mohammed
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Nora Tariq Mohammed, University of Duhok
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07141823
- Sponsor's protocol ID
- UoD-ODNS-2025-01
- Acronym
- DNA Damage
- Status last verified
- Jul 2025
- First submitted
- 16 Jul 2025
- Last updated
- 26 Aug 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Oxidative DNA Damage Enhancement by Vitamin C Among Narghile Smokers and Non-smokers
- ClinicalTrials.gov ID
- NCT07141823
- Acronym / sponsor ID
- DNA Damage / UoD-ODNS-2025-01
- Conditions
- Narghile
- Keywords
- DNA damage, Oxidative stress ,MDA, vitamin C
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 96 participants (actual)
- Lead sponsor
- Nora Tariq MohammedUniversity, hospital or other
- Study start
- 15 Oct 2024 (actual)
- Primary completion
- 10 Dec 2024 (actual)
- Study completion
- 10 Mar 2025 (actual)
- First posted
- 26 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate oxidative DNA damage among hookah smokers compared to non-smokers by measuring biomarkers of oxidative stress in blood samples. The objective is to determine the impact of hookah smoking on DNA integrity and overall oxidative status in adults.
Detailed description
Hookah smoking has become increasingly popular in many regions, yet its potential impact on oxidative stress and DNA integrity is not fully understood. This study aims to investigate the level of oxidative DNA damage among hookah smokers compared to non-smokers by analyzing biomarkers in blood samples. A case-control observational design will be used, involving two groups of adult participants: regular hookah smokers and age-matched non-smokers. Blood samples will be collected from all participants and analyzed for markers of oxidative stress, including 8-hydroxy-2'-deoxyguanosine (8-OHdG) and malondialdehyde (MDA), using validated biochemical methods. The findings are expected to provide insights into the biological consequences of hookah smoking and support the development of public health interventions.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Narghile nonsmokers vitamin C taking | Experimental | Dietary Supplement: Vitamin C (Ascorbic Acid) regularly has been takenthis group of participant take vitamin C for one month, and they are healthy volunteers |
| Narghile smokers | Experimental | Dietary Supplement: Vitamin C (Ascorbic Acid) regularly has been takenthis group take vitamin c supplent for one month period and are healthy. |
Who may qualify
- Ages
- 18 to 30 months
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- Adults aged 18-30 years
- Current narghile (hookah) smokers for at least 1 year
- Willing to provide informed consent
Key exclusion criteria (1 listed)
- Healthy participant
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vitamin C (Ascorbic Acid) regularly has been taken | Dietary supplement | Narghile nonsmokers vitamin C taking, Narghile smokers |
Primary outcome
Oxidative DNA damage
Time frame: Baseline and after 1 month
Measurement of plasma MDA concentration using the thiobarbituric acid reactive substances (TBARS) method to assess oxidative stress in participants before and after 1-month Vitamin C supplementation and measuring oxidative stress marker and TAOC
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2025.
Related trials for Narghile
Recruiting
Feasibility and Uptake of Low-Dose CT Lung Cancer Screening in Kuwait
Lung Cancer, Lung Neoplasms
Active, not recruiting
Secondhand Effects of Hookah (i.e., Waterpipe) Smoke and Aerosol
Hookah Smoking, Secondhand Aerosol
Not yet recruiting
Evaluating the Efficacy of a Text Messaging-based Shisha Smoking Cessation Intervention
Intervention, Control
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Vitamin C (Ascorbic Acid) regularly has been taken in people with Narghile, run by Nora Tariq Mohammed at 1 site in Iraq.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Iraq. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Oxidative DNA damage (time frame: Baseline and after 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2025.